Medsurant Holdings

Medsurant Holdings specializes in providing advanced neurodiagnostic services, focusing on Intraoperative Neuromonitoring (IONM) and Electroneurodiagnostic (END) testing to ensure optimal patient outcomes during surgical procedures. Medsurant Holdings was founded in 2011 and is headquartered in Denver, US. The company provides neurodiagnostic services and has completed a total of 3 deals. The founder’s background is not specified, and no notable pivots or changes in business strategy have been reported.

Medsurant Holdings was acquired by New Capital Partners, though the financial terms of this deal remain undisclosed. Medsurant Monitoring specializes in providing advanced neurodiagnostic services, primarily focusing on Intraoperative Neuromonitoring (IONM) and Electroneurodiagnostic (END) testing. Their core offerings include continuous monitoring during surgical procedures to assess neurological function and prevent potential complications, as well as comprehensive EEG services for diagnosing various neurological conditions. The company's highly qualified technologists, all certified with extensive fellowship experience in the Electroneurodiagnostic field, deliver these services to healthcare institutions, including hospitals and surgical centers, operating in multiple geographical markets across the United States.

They cater to a diverse client base that includes neurosurgeons, anesthesiologists, and other medical professionals requiring reliable neurodiagnostic support for their patients. Medsurant Monitoring generates revenue primarily through contracts with healthcare providers for their IONM and EEG services. The company typically engages in B2B transactions, where surgical centers and hospitals pay for neurodiagnostic services on a per-case basis or through ongoing service agreements. These agreements may include bundled pricing for multiple surgeries or ongoing monitoring services, with revenue derived from real-time monitoring during surgeries and diagnostic testing that supports patient evaluation and treatment plans.

Their flagship services are recognized for quality and reliability in the healthcare industry, contributing to strong client retention within the neurodiagnostics market. Medsurant Holdings plans to utilize the recent acquisition by New Capital Partners to expand its service offerings and geographic reach. Upcoming products in development or launch are not specified. The company aims to penetrate new markets within the U.

S. healthcare system, although specific regions and timelines for these expansions have not been disclosed. Funding from the acquisition will likely support these growth initiatives.